Initial treatment of CLL

Typical Treatment of Chronic Lymphocytic Leukemia

Initial treatment of CLL · A BTK inhibitor such as ibrutinib (Imbruvica), zanubrutinib (Brukinsa), or acalabrutinib (Calquence), either alone or ...

First treatment for chronic lymphocytic leukaemia (CLL)

The main treatments for chronic lymphocytic leukaemia are targeted cancer drugs. You might have a combination of a targeted cancer drug with other anti cancer ...

First-line therapy for chronic lymphocytic leukemia

First-line therapies used to treat chronic lymphocytic leukemia (CLL) are targeted therapy and chemoimmunotherapy.

Chronic Lymphocytic Leukemia Treatment - NCI

Signs and symptoms of CLL include swollen lymph nodes and feeling tired. · Painless swelling of the lymph nodes in the neck, underarm, stomach, ...

Selecting initial therapy in CLL - PMC - PubMed Central

Except for selected young, fit patients with a mutated immunoglobulin heavy chain variable region gene, most patients benefit from targeted ...

Chronic Lymphocytic Leukemia (CLL) Treatment & Management

Monotherapy with the alkylating chemotherapy agents, including chlorambucil, had been the first-line therapy for several years. Chlorambucil ...

Initial treatment of CLL: integrating biology and functional status

Chemoimmunotherapy (CIT) has been the standard first-line therapy for CLL. Age and comorbidities can help decide which patients may benefit from a CIT approach.

Chronic Lymphocytic Leukemia Treatment (PDQ®) - NCI

Chronic lymphocytic leukemia (CLL) treatment options can include observation, steroids, chemotherapy, targeted therapy, and/or stem cell ...

Treatments for chronic lymphocytic leukemia | Canadian Cancer ...

Treatments for relapsed or refractory chronic lymphocytic leukemia (CLL) include targeted therapy, chemoimmunotherapy and a stem cell transplant.

How We Treat Chronic Lymphocytic Leukemia

Several oral targeted agents have also recently been approved for treatment of CLL. These include ibrutinib, idelalisib, venetoclax, acalabrutinib, and ...

Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)

Prior to a stem cell transplant, "conditioning" therapy is given with chemotherapy or radiation. This kills cancer cells but also destroys ...

Time-Limited Initial Therapy for Young, Fit Patients with CLL

A flurry of interest has emerged in clinical trials that combine these two most effective regimens for CLL — with a BTK inhibitor plus ...

First-Line Treatment of Older Patients with CLL - PubMed Central

Venetoclax is the first BCL2 inhibitor and was approved by the FDA and EMA for the treatment of CLL following the publication of studies that showed its ...

First line therapy of CLL - Hallek - 2023 - Wiley Online Library

3.1.1 Ibrutinib ... Ibrutinib was the first BTK inhibitor to be tested and approved for the treatment of CLL. ... The RESONATE-2 trial established ...

Overview of the treatment of chronic lymphocytic leukemia - UpToDate

Outline · Indications for treatment ("active disease") · Patients without "active disease" · - Early-stage asymptomatic CLL · Initial observation ...

Chronic lymphocytic leukemia treatment algorithm 2022 - Nature

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very ...

Factors to consider when selecting initial therapy in CLL - VJHemOnc

The two main options for initial treatment of chronic lymphocytic leukemia (CLL) are continuous BTK inhibitor therapy, ...

Initial therapy of chronic lymphocytic leukemia - ScienceDirect.com

Prognostic risk factor profile and comorbidity burden are most relevant for the choice of treatment. For physically fit patients, chemoimmunotherapy with ...

Treatment for chronic lymphocytic leukaemia (CLL)

If you have very early stage CLL, doctors usually wait until there are signs of progression before suggesting treatment. There is no evidence that starting ...

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic ...

1 deletion (typically 5 to 10% of previously untreated patients with CLL). Ibrutinib substantially improved overall survival, with an overall ...